CNS Pharmaceuticals (CNSP) Cash from Financing Activities (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Cash from Financing Activities came in at $406872.0 in Q4 2025, down 91.8% YoY from $5.0 million in Q4 2024, and up 544.11% on a QoQ basis from -$91616.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Cash from Financing Activities (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 8 years of Cash from Financing Activities data on file, last reported at $406872.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 91.8% year-over-year to $406872.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.6 million (down 36.74% YoY) and the FY2025 annual result came in at $14.6 million, down 36.74% from the prior year.
- Cash from Financing Activities improved to $406872.0 in Q4 2025, from -$91616.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $12.3 million in Q3 2024 to a low of -$120284.0 in Q1 2023.
- A 5-year average of $3.1 million and a median of $2.3 million in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 114.37% — and 2024, when it jumped 146826.13%.
- Tracing CNSP's Cash from Financing Activities over 5 years: stood at -$82828.0 in 2021, then soared by 6538.96% to $5.3 million in 2022, then tumbled by 59.17% to $2.2 million in 2023, then surged by 127.92% to $5.0 million in 2024, then plunged by 91.8% to $406872.0 in 2025.
- The last three Cash from Financing Activities figures came in at $406872.0 (Q4 2025), -$91616.0 (Q3 2025), and $4.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 406,872.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 406,872.00 |
| Dec 31, 2025 | 406,872.00 |
| Sep 30, 2025 | -91,616.00 |
| Sep 30, 2025 | -91,616.00 |
| Jun 30, 2025 | 4.43 Mn |
| Jun 30, 2025 | 4.43 Mn |
| Mar 31, 2025 | 9.83 Mn |
| Mar 31, 2025 | 9.83 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Dec 31, 2024 | 4.96 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Sep 30, 2024 | 12.28 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Dec 31, 2023 | 2.18 Mn |
| Dec 31, 2023 | 2.18 Mn |
| Sep 30, 2023 | 8,359.00 |
| Sep 30, 2023 | 8,359.00 |